Cerevel Therapeutics Holdings Inc (CERE) Actualités

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form 8-K - Current report

CERE MERGER ANNOUNCEMENT: Julie & Holleman LLP Announces Investigation Into Potential Claims Regarding AbbVie's Proposed Acquisition of Cerevel Therapeutics

CERE MERGER ANNOUNCEMENT: Julie & Holleman LLP Announces Investigation Into Potential Claims Regarding...

AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline

AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline PR Newswire NORTH CHICAGO, Ill. and...

Form 144 - Report of proposed sale of securities

Cerevel Therapeutics to Host Investor Webcast on Tavapadon in Parkinson’s Disease

Event will focus on tavapadon, a D1/D5 partial agonist in Phase 3 development for the treatment of Parkinson’s...

Cerevel Therapeutics to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated...

Form 8-K - Current report

Cerevel Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates

Raised $499 million of net proceeds from public offering of common stock, expected to support operations into...